Production issues could put a damper on Novo Nordisk's 2022

Novo Nordisk’s supply issues of its obesity drug, Wegovy, are blurring the company’s growth outlook and creating doubts about its 2022 guidance, reports Danish media Børsen.

Photo: Novo Nordisk / PR

Analysts and investors are concerned about Novo Nordisk’s current production problems with obesity drug Wegovy, which have arisen due to issues at the Danish pharmaceutical company’s contract manufacturer, Catalent, reports Danish business media Børsen.

J.P. Morgan has lowered its sales estimate for Wegovy by 40 percent for 2022 and is now expecting sales to reach DKK 5.5bn (USD 832.7m), and Swiss UBS is also cautious, predicting that the current uncertainties will have an impact on Novo Nordisk’s 2022 guidance.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs